Long chain omega-3 dietary supplements: A review of the national library of medicine herbal supplement database

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 4, 2011, Pages 255-271

  Zargar, Atanaz ^a   Ito, Matthew K ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; RETINOL; VITAMIN D;

ARTICLE; COST; COST BENEFIT ANALYSIS; DIET SUPPLEMENTATION; DIETARY REFERENCE INTAKE; FOOD AND DRUG ADMINISTRATION; LIBRARY; PRIORITY JOURNAL; REFERENCE DATABASE;

DATABASES, FACTUAL; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FISH OILS; HUMANS; NATIONAL LIBRARY OF MEDICINE (U.S.); NUTRITION POLICY; UNITED STATES;

EID: 79960814823     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2011.0004     Document Type: Article

References (36)

1. Ashar BH, Rowland-Seymour A. Advising patients who use dietary supplements. Am J Med 2008;121:91-97. (Pubitemid 351199475)
2. Sadosvsky R, Collins N, Tighe AP, Brunton SA, Safeer R. Patient use of dietary supplements: A clinician's perspective. Curr Med Res Opin 2008;24:1209-1216. (Pubitemid 351579180)
3. Morrow JD. Why the United States still needs improved dietary supplement regulation and oversight. Clin Pharmacol Ther 2008;83:391-393. (Pubitemid 351278392)
4. Fish Oil becomes most popular dietary supplement. Reported by Consumerlab.com. Available at: http://healthnewsdigest.com/news/Research-270/ Fish-Oil-Becomes-Most-Popular-Dietary-Supplement.shtml/ Accessed on June 20, 2010.
5. Health & Wellness Trends Drive Growth in All Retail Channels May 1, 2004. Available at: http://subscribers.nutritionbusinessjournal.com/retail/ health-wellness-trendsdrive-growth-0504/wall.html?return=http://subscribers. nutritionbusinessjournal.com/retail/health-wellness-trendsdrive-growth-0504/ index.html/ Accessed on June 20, 2010.
6. Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997;336:1046-1053. (Pubitemid 27163856)
7. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-1209. (Pubitemid 15009153)
8. Burr MI, Fehily AM, Gilbert JF,Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet And Reinfaction Trial (DART). Lancet 1989;2:757-761. (Pubitemid 19234807)
9. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzion trial Gruppo Italiano per lo studios della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447-455.
10. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-1230.
11. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatak e A, Nakaya N, Sakata T, Shimada K, Shirato K. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomized openlabel,blinded endpoint analysis. [published correction appears in Lancet 2007;370:220]. Lancet 2007;69:1090-1098. (Pubitemid 46483662)
12. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-2026.
13. Rauch B, Schiele R, Schneider S, Diller F, Victor N, GohlkeH, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-2159.
14. Wujendran V, Hayes KC. Dietary n-6 and n-3 fatty acid balance and cardiovascular health. Anu Prev Nutr 2004;24:597-615. (Pubitemid 38938805)
15. Roth EM, Harris WS. Fish oil for primary and secondary prevention of coronary heart disease. Curr Atheroscler Rev 2010;12:66-72.
16. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 2006;98(4A): 27i-33i.
17. Krauss RM. Hold the antioxidants and improve plasmalipids? J Clin Invest 2004;113:1253-1255.
18. Park Y, Haris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44:455-463. (Pubitemid 37279692)
19. Bays H. Rational for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia:a primer for clinicians. Drugs Today (Barc) 2008;44:205-246. (Pubitemid 351669107)
20. Kris-Etherton PM, Harris WS, Appel LJ, for the AHA Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-2757. (Pubitemid 35364932)
21. Skinner JS, Cooper A, Feder GS. Secondary prevention for patients after a myocardial infarction: summary of NICE guidance. BMJ 2007;334:1112-1113. (Pubitemid 46867134)
22. Product monograph and prescribing information. Lovaza(omega-3-acid ethyl esters). Available at: http://us.gsk.com/products/assets/us-lovaza.pdf/ Accessed December 22, 2010.
23. Irishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007;15:257-263.
24. Lopez JAG, Ito MK. PLA Chapter Update: Prescription fish oil and Blue Cross of Idaho. Lipid Spin 2010;8:32-34.
25. The United States National Library of Medicine DietarySupplements Labels Database. Available at: http://dietarysupplements.nlm.nih.gov/dietary/ Accessed on October 18,2009.
26. United State Pharmacopeia (USP). Available at: http://www.usp.org/ USPVerified/dietarySupplements/supplements.html/ Accessed on March 9, 2010.
27. Office of Dietary Supplements National Institute of Health. Nutrient Recommendations. Available at: http://ods.od.nih.gov/HealthInformation/ nutrientrecommendations.sec.aspx/Accessed on March 10, 2010.
28. Medco Medicare Prescription Drug Plan. Available at: http://www. marylandspdap.com/Portals/1/Docs-MarylandSPDAP/2011-MedCo-PDPs.pdf/ Accessed on December 20, 2010.
29. CVS Caremark Prescription Drug Plan. Available at: http://www. marylandspdap.com/Portals/1/Docs-MarylandSPDAP/2011-CVS-PDPs.pdf/ Accessed on December 20, 2010.
30. BlueCross BlueShield PPO. Available at: http://www.bcbsga.com/member/ emory/memberhome/nosecondary/notertiary/pw-a105425.pdf/ Accessed on December 20, 2010.
31. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED.Long-term adherence with cardiovascular drug regimens.Am Heart J 2006;151:185-191. (Pubitemid 41815352)
32. Dietary Supplement Current Good Manufacturing Practices(CGMPs) and Interim Final Rule (IFR) Facts. June 22, 2007.Available at: http://www.fda.gov/ Food/DietarySupplements/GuidanceComplianceRegulatoryInformation/RegulationsLaws/ ucm110858.htm/ Accessed on December 20, 2010.
33. Tips For The Savvy Supplement User: Making Informed Decisions And Evaluating Information. January 2002. Available at: http://www.fda.gov/food/ dietarysupplements/consumerinformation/ucm110567.htm/ Accessed on December 20, 2010.
34. Harris W, Ginsberg H, Arunakul, Shachter NS, Windsor SL, Adams M, Berglund L, Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-391. (Pubitemid 28078682)
35. Ho PM, Magid DJ, Sheterly S, Olson K, Maddos TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-779. (Pubitemid 351410514)
36. Hutchison AJ, Laville M. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008;23:3677-3684.